FDA approves CAD system for lung cancer screening

Article

Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest

Deus Technologies got the nod from the FDA to begin selling its RapidScreen RS-2000 to assist in the detection of early-stage lung cancer. The computer-assisted detection system digitizes and analyzes chest radiographs to identify regions of interest that may have features associated with early-stage lung cancer. The system uses image enhancement and pattern recognition techniques to locate suspicious areas that may warrant a second review by a radiologist. Deus developed the software using thousands of existing chest images as training data sets. The software contains elements of artificial neural networks and fuzzy logic technology.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.